Development

Ocugen launches Phase III trial of one-time gene therapy for geographic atrophy

Edited by Robert McTiernan··3 min read
Ocugen launches Phase III trial of one-time gene therapy for geographic atrophy

Ocugen (Nasdaq: OCGN) has dosed the first patient in ArMaDa3, a global Phase III registrational trial of OCU410, an AAV5-based modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration. The company describes ArMaDa3 as the first pivotal gene therapy trial in GA, marking a notable development in a field where approved treatments require repeated intravitreal injections and have not consistently demonstrated corresponding functional vision benefits.

OCU410 delivers the retinoid-related orphan receptor alpha (RORA) gene through an AAV5 vector with the aim of modulating complement activation, neuroinflammation, oxidative stress, and lipid dysregulation. The approach differs from the two approved US GA drugs, Apellis Pharmaceuticals' Syfovre (pegcetacoplan), a C3 inhibitor, and Astellas Pharma's Izervay (avacincaptad pegol), a C5 inhibitor. Izervay is also approved in Australia and Macau and conditionally approved in Japan, while Syfovre failed to secure EU approval following a negative EMA review.

ArMaDa3 will enroll 237 patients with GA secondary to dry AMD and randomize them 2:1 to a single 200 µL subretinal injection of OCU410 or an untreated control. The primary endpoint is the rate of change in square root-transformed GA lesion area by fundus autofluorescence at 12 months. Secondary measures include sustained loss of at least 15 ETDRS letters in low-luminance visual acuity and change in ellipsoid zone area by optical coherence tomography.

The study design followed a July 2026 Type B End-of-Phase 2 meeting with the US FDA's Center for Biologics Evaluation and Research, where Ocugen said it reached alignment on the dose, endpoints, and use of a single adequate and well-controlled Phase III study to support a potential Biologics License Application. The company is targeting a BLA filing in 2028 and is also engaging the EMA on whether the same dataset could support a European filing.

The program received FDA Regenerative Medicine Advanced Therapy designation in July 2026 based on Phase II data. RMAT provides benefits available under Breakthrough Therapy designation, including intensive FDA interaction and potential rolling review, while accelerated approval or priority review would remain subject to the relevant regulatory criteria.

The AllSci BriefSystematic R&D and deal news. Daily.

The Phase III study is supported by 12-month Phase II ArMaDa data from 51 patients. Ocugen reported a statistically significant 31% reduction in GA lesion growth at the selected medium dose versus untreated control, alongside a 27% reduction in ellipsoid zone loss. Seventy-five percent of treated patients showed more than 30% reduction in lesion growth, and no OCU410-related serious adverse events or adverse events of special interest were reported.

Ocugen has said the 31% lesion-growth reduction compares favorably with effects reported for Syfovre and Izervay, although cross-trial comparisons are limited by the small Phase II sample and differences in study design, including ArMaDa's untreated control versus the sham-controlled pivotal trials used for the approved complement inhibitors.

OCU410 also has Advanced Therapy Medicinal Product classification from the EMA. If a single administration can produce durable benefit, the approach could reduce the treatment burden associated with chronic complement inhibition. The central Phase III questions will be whether the Phase II anatomical benefit is reproduced in a larger registrational population and whether it translates into sustained functional benefit.

Access the AllSci platform to explore the science behind the news.

Spot something wrong? Report an issue with this article